This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.
Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International
by Zacks Equity Research
Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International
Boston Scientific Rides on New Products Amid Dull Pacer Sales
by Zacks Equity Research
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Baxter (BAX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Canopy Growth Set to Acquire Beckley Canopy Therapeutics
by Zacks Equity Research
With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.
5 Stocks Trading Near 52-Week High With More Room to Run
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised
by Zacks Equity Research
Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.
Nevro (NVRO) Q2 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro (NVRO) sees dismal segmental performance in Q2.
Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered
by Zacks Equity Research
Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Allscripts (MDRX) Q2 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.
Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss
by Zacks Equity Research
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.
LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group (LHCG) second-quarter results benefit from home health and hospice admissions and higher revenues.
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.
OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from RAYALDEE prescriptions in Q2.
Wright Medical (WMGI) Earnings Beat in Q2, Guidance Slashed
by Zacks Equity Research
Wright Medical (WMGI) gains from Upper and Lower Extremities units in Q2; slashes 2019 view.
Cardiovascular Systems (CSII) Earnings Match Estimates in Q4
by Zacks Equity Research
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
CVS Health (CVS) Beats on Q2 Earnings, Raises '19 Guidance
by Zacks Equity Research
CVS Health's (CVS) second-quarter top-line growth in Pharmacy Services segment is backed by an uptick in specialty services.
Avanos (AVNS) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Avanos (AVNS) second-quarter results benefit from higher revenues, strong segmental performance and expansion in margins.
AMN Healthcare (AMN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare (AMN) issues upbeat revenue guidance for the third quarter of 2019.
Syneos Health (SYNH) Q2 Earnings Beat Estimates, '19 View Up
by Zacks Equity Research
We are upbeat about Syneos Health's (SYNH) strong year-over-year revenue growth across both operating segments.
Insulet (PODD) Misses on Q2 Earnings, Ups '19 Revenue View
by Zacks Equity Research
The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.
STERIS (STE) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in Q1.